Skip to main content

TCG Crossover Management, LLC

13F filer · CIK 0001839948
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$4.16BU.S. long equity reported on 13F
Positions5412 new · 7 closed
Net flow last quarter-$20.3MBuys minus sells
Top 10 positions weight57.4%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202654 positions
ABVXAbivax S.A.$801M19.24%7.65%-7.3%Q4 2023
TNGXTango Therapeutics, Inc.$284M6.82%5.39%-13.8%Q1 2022
CGONCG Oncology, Inc.$261M6.27%4.16%Not reportedQ1 2024
COGTCogent Biosciences, Inc.$188M4.52%2.83%-1.9%Q4 2021
IMVTImmunovant, Inc.$172M4.13%2.16%Not reportedQ4 2022
SYRESpyre Therapeutics, Inc.$169M4.06%2.16%Not reportedQ3 2025
DNTHDianthus Therapeutics, Inc.$163M3.93%3.06%Not reportedQ4 2024
MIRMMirum Pharmaceuticals, Inc.$124M2.99%1.64%Not reportedQ4 2025
ZLABZai Lab Ltd$117M2.80%0.55%Not reportedQ4 2021
AMLXAmylyx Pharmaceuticals, Inc.$112M2.70%5.61%Not reportedQ3 2024
GLUEMonte Rosa Therapeutics, Inc.$112M2.69%5.42%Not reportedQ4 2025
BCRXBiocryst Pharmaceuticals Inc$110M2.65%4.32%Not reportedQ1 2026
VORVor Biopharma Inc.$104M2.51%10.42%Not reportedQ1 2026
TYRATyra Biosciences, Inc.$104M2.49%5.45%Not reportedQ4 2021
DYNDyne Therapeutics, Inc.$103M2.46%2.79%Not reportedQ1 2023
IRONDisc Medicine, Inc.$98.1M2.36%3.50%Not reportedQ2 2024
RLAYRelay Therapeutics, Inc.$80M1.92%1.96%Not reportedQ3 2025
SVRASavara Inc$76.2M1.83%6.02%Not reportedQ3 2023
AURAAura Biosciences, Inc.$67.7M1.63%9.21%NewQ2 2026
RVMDRevolution Medicines, Inc.$63.8M1.53%0.16%-40.9%Q3 2025
TRAXFirst Tracks Biotherapeutics, Inc.$58.3M1.40%8.18%NewQ2 2026
KODKodiak Sciences Inc.$56.3M1.35%2.30%Not reportedQ4 2023
AVTXAvalo Therapeutics, Inc.$55.8M1.34%5.70%+308.6%Q3 2024
LBRXLB Pharmaceuticals Inc$47M1.13%5.05%-21.3%Q3 2025
IPSCCentury Therapeutics, Inc.$43.4M1.04%9.83%Not reportedQ1 2026
TECXTectonic Therapeutic, Inc.$41.4M1.00%6.26%Not reportedQ1 2026
XNCRXencor Inc$39.5M0.95%3.30%Not reportedQ3 2024
SRZNSurrozen, Inc.$38.2M0.92%12.53%Not reportedQ1 2026
EDITEditas Medicine, Inc.$36M0.87%11.35%NewQ2 2026
MBXMBX Biosciences, Inc.$35.9M0.86%1.36%Not reportedQ3 2024
PHVSPharvaris N.V.$34.9M0.84%1.55%NewQ2 2026
SLNSilence Therapeutics plc$33.3M0.80%2.14%Not reportedQ3 2022
IFRXInflaRx N.V.$32.5M0.78%20.06%NewQ2 2026
ALTAltimmune, Inc.$30.4M0.73%5.14%NewQ2 2026
JANXJanux Therapeutics, Inc.$27.5M0.66%2.93%Not reportedQ4 2025
CATXPerspective Therapeutics, Inc.$27M0.65%6.94%Not reportedQ1 2026
AGMBAgomab Therapeutics NV$26.7M0.64%6.01%Not reportedQ1 2026
BHVNBiohaven Ltd.$26.5M0.64%1.18%-61.6%Q4 2025
AKTSAktis Oncology, Inc.$22.5M0.54%1.30%NewQ2 2026
ALECAlector, Inc.$20.1M0.48%8.96%Not reportedQ4 2025
FBRXForte Biosciences, Inc.$19.6M0.47%4.49%NewQ2 2026
MNPRMonopar Therapeutics$18.8M0.45%3.03%+53.9%Q3 2025
OCULOcular Therapeutix, Inc$16.2M0.39%0.75%Not reportedQ1 2024
ADCTADC Therapeutics SA$12.2M0.29%8.94%Not reportedQ3 2025
ALXOAlx Oncology Holdings Inc$11.7M0.28%4.09%-56.5%Q1 2026
TRDAEntrada Therapeutics, Inc.$7.8M0.19%2.72%-53.7%Q4 2021
CGEMCullinan Therapeutics, Inc.$7.41M0.18%0.63%Not reportedQ1 2026
ARVNArvinas, Inc.$5.88M0.14%1.08%-70.4%Q3 2025
KRROKorro Bio, Inc.$5.49M0.13%2.83%Not reportedQ3 2025
RACCResearch Alliance Corp III$5.35M0.13%Not reportedNewQ2 2026
Q1 2026Reported May 15, 202649 positions
ABVXAbivax S.A.$722M20.65%8.25%-8.9%Q4 2023
CGONCG Oncology, Inc.$248M7.11%4.17%Not reportedQ1 2024
TNGXTango Therapeutics, Inc.$220M6.30%7.31%-17.5%Q1 2022
COGTCogent Biosciences, Inc.$190M5.45%2.90%-15.7%Q4 2021
CNTACentessa Pharmaceuticals PLC$170M4.87%2.77%Not reportedQ3 2023
DNTHDianthus Therapeutics, Inc.$141M4.03%3.07%Not reportedQ4 2024
TYRATyra Biosciences, Inc.$124M3.56%5.46%+12.1%Q4 2021
IMVTImmunovant, Inc.$111M3.17%2.19%+168.4%Q4 2022
BCRXBiocryst Pharmaceuticals Inc$105M3.00%4.34%NewQ1 2026
MIRMMirum Pharmaceuticals, Inc.$98.1M2.81%1.74%+1611.6%Q4 2025
VORVor Biopharma Inc.$96.5M2.76%10.47%NewQ1 2026
SYRESpyre Therapeutics, Inc.$95.9M2.74%2.41%Not reportedQ3 2025
AMLXAmylyx Pharmaceuticals, Inc.$86.8M2.48%5.62%Not reportedQ3 2024
IRONDisc Medicine, Inc.$85.8M2.45%3.51%Not reportedQ2 2024
DYNDyne Therapeutics, Inc.$83.7M2.39%2.79%Not reportedQ1 2023
GLUEMonte Rosa Therapeutics, Inc.$76M2.18%5.48%Not reportedQ4 2025
SVRASavara Inc$67.5M1.93%6.03%Not reportedQ3 2023
RVMDRevolution Medicines, Inc.$56.1M1.60%0.29%+32.1%Q3 2025
KODKodiak Sciences Inc.$55.1M1.58%2.33%Not reportedQ4 2023
LBRXLB Pharmaceuticals Inc$45.3M1.30%6.42%+5.4%Q3 2025
SRZNSurrozen, Inc.$42.9M1.23%12.82%NewQ1 2026
ADCTADC Therapeutics SA$42.7M1.22%8.96%Not reportedQ3 2025
RLAYRelay Therapeutics, Inc.$42.5M1.22%2.26%+32.7%Q3 2025
FULCFulcrum Therapeutics, Inc.$40.3M1.15%7.88%Not reportedQ3 2024
BHVNBiohaven Ltd.$39.2M1.12%3.08%Not reportedQ4 2025
IPSCCentury Therapeutics, Inc.$39M1.12%9.86%NewQ1 2026
TECXTectonic Therapeutic, Inc.$37.2M1.07%6.40%NewQ1 2026
CATXPerspective Therapeutics, Inc.$33M0.94%6.94%NewQ1 2026
XNCRXencor Inc$29.6M0.85%3.31%Not reportedQ3 2024
TRDAEntrada Therapeutics, Inc.$28.9M0.83%5.89%+9.5%Q4 2021
ALXOAlx Oncology Holdings Inc$26.1M0.75%9.41%NewQ1 2026
ARVNArvinas, Inc.$25.3M0.72%3.70%-10.5%Q3 2025
JANXJanux Therapeutics, Inc.$24.9M0.71%2.94%Not reportedQ4 2025
AGMBAgomab Therapeutics NV$21.5M0.62%6.01%NewQ1 2026
ALECAlector, Inc.$21.5M0.62%9.01%Not reportedQ4 2025
MBXMBX Biosciences, Inc.$19.4M0.56%1.37%Not reportedQ3 2024
SLNSilence Therapeutics plc$16M0.46%2.14%Not reportedQ3 2022
LQDALiquidia Corp$15.2M0.44%0.46%-76.4%Q3 2025
OCULOcular Therapeutix, Inc$14M0.40%0.75%-71.3%Q1 2024
AVTXAvalo Therapeutics, Inc.$11M0.32%3.00%+52.9%Q3 2024
URGNUroGen Pharma Ltd.$7.29M0.21%0.83%-43.5%Q3 2025
MNPRMonopar Therapeutics$7.24M0.21%1.97%-6.9%Q3 2025
CNTXContext Therapeutics Inc.$7.03M0.20%2.92%NewQ1 2026
GPCRStructure Therapeutics Inc.$6.77M0.19%0.07%-84.8%Q1 2023
CGEMCullinan Therapeutics, Inc.$5.78M0.17%0.66%NewQ1 2026
KRROKorro Bio, Inc.$4.71M0.13%2.89%Not reportedQ3 2025
LONALeonaBio, Inc.$4.67M0.13%4.94%Not reportedQ4 2025
UPBUpstream Bio, Inc.$1.63M0.05%0.33%-75.7%Q4 2024
VTGNVistagen Therapeutics, Inc.$1.53M0.04%6.76%Not reportedQ4 2023
Q4 2025Reported Feb 17, 202643 positions
ABVXAbivax S.A.$959M31.74%9.06%Not reportedQ4 2023
COGTCogent Biosciences, Inc.$208M6.90%3.65%-13.7%Q4 2021
CGONCG Oncology, Inc.$152M5.04%4.55%Not reportedQ1 2024
TNGXTango Therapeutics, Inc.$113M3.74%9.39%+49.5%Q1 2022
CNTACentessa Pharmaceuticals PLC$107M3.55%2.87%+36.7%Q3 2023
DYNDyne Therapeutics, Inc.$90.3M2.99%2.80%Not reportedQ1 2023
RAPTRAPT Therapeutics, Inc.$87.5M2.89%9.32%+57.8%Q4 2024
TYRATyra Biosciences, Inc.$76.2M2.52%5.40%Not reportedQ4 2021
AMLXAmylyx Pharmaceuticals, Inc.$75.4M2.50%5.68%Not reportedQ3 2024
SVRASavara Inc$74.5M2.47%6.04%Not reportedQ3 2023
GLUEMonte Rosa Therapeutics, Inc.$72.5M2.40%7.05%NewQ4 2025
OCULOcular Therapeutix, Inc$69.7M2.31%2.66%-6.2%Q1 2024
DNTHDianthus Therapeutics, Inc.$69.1M2.29%3.88%Not reportedQ4 2024
EYPTEyePoint, Inc.$65.3M2.16%4.31%Not reportedQ2 2024
GPCRStructure Therapeutics Inc.$64M2.12%0.43%-13.4%Q1 2023
SYRESpyre Therapeutics, Inc.$62.3M2.06%2.43%+72.7%Q3 2025
FULCFulcrum Therapeutics, Inc.$59.4M1.97%7.89%Not reportedQ3 2024
LQDALiquidia Corp$59M1.95%1.96%Not reportedQ3 2025
BHVNBiohaven Ltd.$52.3M1.73%3.49%NewQ4 2025
IMVTImmunovant, Inc.$42.2M1.40%0.82%Not reportedQ4 2022
KODKodiak Sciences Inc.$40.4M1.34%2.34%+26.2%Q4 2023
ADCTADC Therapeutics SA$40.2M1.33%9.06%+719.3%Q3 2025
LBRXLB Pharmaceuticals Inc$38.8M1.29%6.90%0.0%Q3 2025
XNCRXencor Inc$37.5M1.24%3.41%Not reportedQ3 2024
RVMDRevolution Medicines, Inc.$34.8M1.15%0.22%Not reportedQ3 2025
AGIOAgios Pharmaceuticals, Inc.$32.2M1.06%2.02%-17.4%Q2 2025
ARVNArvinas, Inc.$31.6M1.05%4.20%+64.9%Q3 2025
RLAYRelay Therapeutics, Inc.$27.2M0.90%1.85%+77.9%Q3 2025
JANXJanux Therapeutics, Inc.$24.7M0.82%2.96%NewQ4 2025
TRDAEntrada Therapeutics, Inc.$21.5M0.71%5.46%+257.0%Q4 2021
MBXMBX Biosciences, Inc.$20.5M0.68%1.45%Not reportedQ3 2024
UPBUpstream Bio, Inc.$20.2M0.67%1.37%-64.9%Q4 2024
SLNSilence Therapeutics plc$18.4M0.61%2.14%Not reportedQ3 2022
URGNUroGen Pharma Ltd.$16.8M0.56%1.48%Not reportedQ3 2025
ALECAlector, Inc.$15.6M0.52%9.06%NewQ4 2025
MNPRMonopar Therapeutics$9.27M0.31%2.12%-7.3%Q3 2025
AVTXAvalo Therapeutics, Inc.$8.77M0.29%2.61%Not reportedQ3 2024
MAZEMaze Therapeutics, Inc.$7.2M0.24%0.35%NewQ4 2025
MIRMMirum Pharmaceuticals, Inc.$4.9M0.16%0.12%NewQ4 2025
LONALeonaBio, Inc.$3.35M0.11%4.97%NewQ4 2025
KRROKorro Bio, Inc.$3.33M0.11%4.42%Not reportedQ3 2025
VTYXVentyx Biosciences, Inc.$2.86M0.09%0.44%Not reportedQ4 2022
VTGNVistagen Therapeutics, Inc.$1.77M0.06%6.78%Not reportedQ4 2023
Q3 2025Reported Nov 17, 202540 positions
ABVXAbivax S.A.$604M29.70%11.23%+17.4%Q4 2023
CGONCG Oncology, Inc.$148M7.27%4.69%Not reportedQ1 2024
COGTCogent Biosciences, Inc.$97.6M4.80%4.86%-2.4%Q4 2021
AMLXAmylyx Pharmaceuticals, Inc.$84.9M4.17%5.69%+5.1%Q3 2024
CNTACentessa Pharmaceuticals PLC$76.1M3.74%2.33%+8.5%Q3 2023
TNGXTango Therapeutics, Inc.$71.7M3.53%7.65%-20.5%Q1 2022
OCULOcular Therapeutix, Inc$71.5M3.52%3.50%+15.0%Q1 2024
DNTHDianthus Therapeutics, Inc.$66M3.25%3.91%+11.7%Q4 2024
TRMLTourmaline Bio, Inc.$62.7M3.09%5.11%-11.2%Q4 2023
DYNDyne Therapeutics, Inc.$58.4M2.87%3.24%+22.5%Q1 2023
AGIOAgios Pharmaceuticals, Inc.$57.4M2.82%2.45%+105.2%Q2 2025
EYPTEyePoint, Inc.$50.9M2.50%5.13%Not reportedQ2 2024
FULCFulcrum Therapeutics, Inc.$48.3M2.38%9.70%Not reportedQ3 2024
SVRASavara Inc$44.1M2.17%7.15%Not reportedQ3 2023
RAPTRAPT Therapeutics, Inc.$42.2M2.08%9.89%Not reportedQ4 2024
TYRATyra Biosciences, Inc.$40.5M1.99%5.44%Not reportedQ4 2021
UPBUpstream Bio, Inc.$39.8M1.96%3.92%-24.4%Q4 2024
LQDALiquidia Corp$38.9M1.91%1.97%NewQ3 2025
IRONDisc Medicine, Inc.$30.7M1.51%1.33%Not reportedQ2 2024
GPCRStructure Therapeutics Inc.$29.8M1.46%0.58%Not reportedQ1 2023
XNCRXencor Inc$28.8M1.41%3.44%Not reportedQ3 2024
LBRXLB Pharmaceuticals Inc$27.6M1.36%6.90%NewQ3 2025
RVMDRevolution Medicines, Inc.$20.4M1.00%0.23%NewQ3 2025
ATXSAstria Therapeutics, Inc.$20.1M0.99%4.89%Not reportedQ1 2024
KRROKorro Bio, Inc.$19.9M0.98%4.43%NewQ3 2025
KODKodiak Sciences Inc.$18.8M0.92%2.16%Not reportedQ4 2023
SYRESpyre Therapeutics, Inc.$18.4M0.91%1.82%NewQ3 2025
SLNSilence Therapeutics plc$15.7M0.77%2.14%Not reportedQ3 2022
URGNUroGen Pharma Ltd.$14.3M0.70%1.53%NewQ3 2025
ARVNArvinas, Inc.$13.8M0.68%2.28%NewQ3 2025
MNPRMonopar Therapeutics$12.5M0.61%2.30%NewQ3 2025
MBXMBX Biosciences, Inc.$11.4M0.56%1.45%Not reportedQ3 2024
VTGNVistagen Therapeutics, Inc.$9.5M0.47%8.72%Not reportedQ4 2023
RLAYRelay Therapeutics, Inc.$9.45M0.46%1.05%NewQ3 2025
ADVMAdverum Biotechnologies, Inc.$7.56M0.37%7.95%-7.1%Q1 2024
AVTXAvalo Therapeutics, Inc.$6.14M0.30%2.71%Not reportedQ3 2024
ADCTADC Therapeutics SA$5.56M0.27%1.23%NewQ3 2025
PEPGPepGen Inc.$5.54M0.27%3.66%NewQ3 2025
TRDAEntrada Therapeutics, Inc.$3.39M0.17%1.53%Not reportedQ4 2021
VTYXVentyx Biosciences, Inc.$983K0.05%0.44%Not reportedQ4 2022
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.